Hepatitis

Advances in hepatitis B management are still not reaching most of the affected community. A major barrier to this translation is stigma. Research and clinical communities have a responsibility to mitigate stigma and ensure that the voices of the affected community are considered in decision-making conversations.

The recent increase in unexplained acute hepatitis in children in 2022 has focused attention on acute paediatric liver disease. We discuss emerging evidence and leading causal hypotheses in context with potential long-term effects of the COVID-19 pandemic for young children.

Only 12 high-income countries are on track to meet the World Health Organization’s goal of eliminating hepatitis C as a public health threat by 2030, and micro-elimination opportunities in high-risk populations in settings such as hospitals are often overlooked. We propose ten steps to eliminate hepatitis C in hospitals.

Hepatitis C virus (HCV) infection is common among people who are incarcerated in low- and middle-income countries. Prison policy changes towards HCV testing and treatment are pivotal for social justice and can be a crucial step for achieving HCV global elimination targets.

Vaccination is a key intervention for the elimination of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections to fulfil the WHO’s 2030 global elimination goal. Innovations in 2021 promise to curb HBV transmission by reducing mother-to-child transmission and enhancing vaccine immunogenicity in at-risk adult groups. Additionally, an HCV vaccination trial was conducted, and there were also advances in our understanding of the immunology underpinning the lack of protection against HCV reinfection.